JP Morgan Chase’s abrdn Life Sciences Investors HQL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-2
| Closed | -$32 | – | 7885 |
|
|
2026
Q1 | $32 | Buy |
+2
| New | +$33 | ﹤0.01% | 7387 |
|
|
2025
Q2 | – | Sell |
-5
| Closed | -$63 | – | 7333 |
|
|
2025
Q1 | $63 | Buy |
+5
| New | +$68 | ﹤0.01% | 6939 |
|
|
2024
Q4 | – | Sell |
-2
| Closed | -$30 | – | 7536 |
|
|
2024
Q3 | $30 | Hold |
2
| – | – | ﹤0.01% | 7200 |
|
|
2024
Q2 | $28 | Hold |
2
| – | – | ﹤0.01% | 7123 |
|
|
2024
Q1 | $27 | Sell |
2
-8,103
| -100% | -$112K | ﹤0.01% | 7129 |
|
|
2023
Q4 | $109K | Buy |
8,105
+8,104
| +810,400% | +$100K | ﹤0.01% | 5698 |
|
|
2023
Q3 | $12 | Sell |
1
-20,710
| -100% | -$272K | ﹤0.01% | 7264 |
|
|
2023
Q2 | $280K | Buy |
20,711
+20,709
| +1,035,450% | +$286K | ﹤0.01% | 4870 |
|
|
2023
Q1 | $0 | Buy |
2
+1
| +100% | +$14 | ﹤0.01% | 6942 |
|
|
2022
Q4 | $0 | Buy |
+1
| New | +$14 | ﹤0.01% | 6743 |
|
|
2022
Q2 | – | Sell |
-4
| Closed | – | – | 6646 |
|
|
2022
Q1 | $0 | Hold |
4
| – | – | ﹤0.01% | 6779 |
|
|
2021
Q4 | $0 | Buy |
4
+3
| +300% | +$60 | ﹤0.01% | 6781 |
|
|
2021
Q3 | $0 | Buy |
+1
| New | +$21 | ﹤0.01% | 6626 |
|
|
2021
Q2 | – | Sell |
-3
| Closed | – | – | 6448 |
|
|
2021
Q1 | $0 | Buy |
3
+2
| +200% | +$41 | ﹤0.01% | 6183 |
|
|
2020
Q4 | $0 | Sell |
1
-1
| -50% | -$18 | ﹤0.01% | 5753 |
|
|
2020
Q3 | $0 | Hold |
2
| – | – | ﹤0.01% | 5593 |
|
|
2020
Q2 | $0 | Buy |
+2
| New | +$34 | ﹤0.01% | 5514 |
|
|
2019
Q4 | – | Sell |
-2
| Closed | – | – | 5728 |
|
|
2019
Q3 | $0 | Buy |
2
+1
| +100% | +$16 | ﹤0.01% | 5832 |
|
|
2019
Q2 | $0 | Hold |
1
| – | – | ﹤0.01% | 5857 |
|
|
2019
Q1 | $0 | Buy |
+1
| New | +$17 | ﹤0.01% | 5893 |
|
|
2017
Q1 | – | Sell |
-20
| Closed | – | – | 5127 |
|
|
2016
Q4 | $0 | Buy |
+20
| New | +$351 | ﹤0.01% | 5056 |
|
|
2016
Q2 | – | Sell |
-11
| Closed | – | – | 4860 |
|
|
2016
Q1 | $0 | Buy |
+11
| New | +$200 | ﹤0.01% | 4794 |
|
|
2014
Q1 | – | Sell |
-26,510
| Closed | -$542K | – | 3731 |
|
|
2013
Q4 | $542K | Buy |
+26,510
| New | +$514K | ﹤0.01% | 3451 |
|
Other funds holding HQL
JP Morgan Chase's HQL Position: Q2 2026 in Review
JP Morgan Chase sold out of abrdn Life Sciences Investors (HQL) in Q2 2026, closing a stake of 2 shares — an estimated $32 sold.
JP Morgan Chase first reported a position in HQL in Q4 2013 and held it in 23 quarters. The position peaked at $542K in Q4 2013. 83 funds tracked by Wall St. Rank hold HQL as of Q2 2026.
- JP Morgan Chase reported no remaining abrdn Life Sciences Investors position as of Q2 2026 after selling out during the quarter.
- JP Morgan Chase sold 2 abrdn Life Sciences Investors shares in Q2 2026, an estimated $32.
- JP Morgan Chase first reported a position in abrdn Life Sciences Investors in Q4 2013 and held it in 23 quarters.
- JP Morgan Chase's abrdn Life Sciences Investors position peaked at $542K in Q4 2013.
- 83 funds tracked by Wall St. Rank held abrdn Life Sciences Investors as of Q2 2026.
Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.